Lifecore Biomedical Inc
NASDAQ:LFCR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.815
8.55
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LFCR stock under the Base Case scenario is 10.9 USD. Compared to the current market price of 7.31 USD, Lifecore Biomedical Inc is Undervalued by 33%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Lifecore Biomedical Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LFCR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Lifecore Biomedical Inc
Balance Sheet Decomposition
Lifecore Biomedical Inc
Current Assets | 74.2m |
Cash & Short-Term Investments | 5.5m |
Receivables | 25.1m |
Other Current Assets | 43.5m |
Non-Current Assets | 172.6m |
PP&E | 151.1m |
Intangibles | 18.1m |
Other Non-Current Assets | 3.4m |
Current Liabilities | 40.5m |
Accounts Payable | 18m |
Accrued Liabilities | 21.1m |
Other Current Liabilities | 1.4m |
Non-Current Liabilities | 166.8m |
Long-Term Debt | 127.2m |
Other Non-Current Liabilities | 39.6m |
Earnings Waterfall
Lifecore Biomedical Inc
Revenue
|
128.4m
USD
|
Cost of Revenue
|
-83.9m
USD
|
Gross Profit
|
44.5m
USD
|
Operating Expenses
|
-50.6m
USD
|
Operating Income
|
-6.1m
USD
|
Other Expenses
|
12.6m
USD
|
Net Income
|
6.5m
USD
|
Free Cash Flow Analysis
Lifecore Biomedical Inc
USD | |
Free Cash Flow | USD |
In its fiscal 2025 first quarter, Lifecore Biomedical reported revenues of $24.7 million, a slight increase from $24.5 million in the prior year. The company achieved a gross profit of $5.4 million, up from $2.7 million, aided by favorable product mix and price hikes. However, net loss widened to $16.2 million. Lifecore closed a $24.3 million PIPE offering, bolstering liquidity, and regained Nasdaq compliance. For fiscal 2025, revenue guidance is set at $126.5 million to $130 million, with expectations of accelerating growth in the second half. Adjusted EBITDA margins are projected to improve toward peers' levels in the sector.
What is Earnings Call?
LFCR Profitability Score
Profitability Due Diligence
Lifecore Biomedical Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Lifecore Biomedical Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
LFCR Solvency Score
Solvency Due Diligence
Lifecore Biomedical Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Lifecore Biomedical Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LFCR Price Targets Summary
Lifecore Biomedical Inc
According to Wall Street analysts, the average 1-year price target for LFCR is 7.14 USD with a low forecast of 6.06 USD and a high forecast of 8.4 USD.
Dividends
Current shareholder yield for LFCR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. The company is headquartered in Chaska, Minnesota and currently employs 689 full-time employees. The firm offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials, as well as the manufacture of pharmaceutical-grade Hyaluronic Acid. The company provides complete CDMO services for injectable pharmaceuticals and medical devices. The Company’s services include sodium hyaluronate, development, manufacturing, and analytical services. The company offers a range of average molecular weights and custom modifications for research and development (R&D), clinical, and commercial applications. The Company’s therapeutic applications include drug delivery, biomaterials, ophthalmology, orthopedics, aesthetics, oncology, and pain management. Its development capabilities include formulation, sterile filtration, filling, packaging, testing, and secondary sterilization.
Contact
IPO
Employees
Officers
The intrinsic value of one LFCR stock under the Base Case scenario is 10.9 USD.
Compared to the current market price of 7.31 USD, Lifecore Biomedical Inc is Undervalued by 33%.